文献速递疼痛医学术前评估与围术期医学

大麻素对慢性神经病理性疼痛患者睡眠健康与疼痛影响的系统综述与Meta分析

Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Reg Anesth Pain Med · 2022-12-05

该系统综述与Meta分析纳入8项随机对照试验,评估大麻素对慢性神经病理性疼痛患者睡眠质量、疼痛强度和整体印象的影响。结果显示大麻素显著改善睡眠质量(SMD 0.40)并降低每日疼痛评分(SMD -0.55),但伴随日间嗜睡、恶心和头晕风险增加。

要点

  • 大麻素可显著改善慢性神经病理性疼痛患者的睡眠质量(SMD 0.40,GRADE中等确定性)。
  • 大麻素显著降低每日疼痛评分(SMD -0.55,GRADE中等确定性)。
  • 睡眠和镇痛获益伴随日间嗜睡、恶心和头晕风险增加。

核心结论

  • 大麻素在治疗慢性神经病理性疼痛中具有作用,表现为睡眠质量、疼痛强度和患者整体印象的显著改善。
  • 需要更多研究全面评估大麻素对睡眠健康和镇痛疗效的影响。

研究设计与样本

  • 系统综述与Meta分析,检索9个医学文献数据库,筛选3491项研究,最终纳入8项随机对照试验,比较合成和天然大麻素与安慰剂在神经病理性疼痛综合征患者中的效果。
  • 使用R 4.1.2的metafor包进行分析,以alpha=0.05为统计显著性阈值。

主要发现

  • 6项研究的Meta分析显示大麻素与睡眠质量显著改善相关(SMD: 0.40; 95% CI: 0.19 to -0.61, 95% PI: -0.12 to 0.88, p-value=0.002, I2=55.26, τ2=0.05, Q-statistic=16.72, GRADE: 中等确定性)。
  • 8项研究的Meta分析显示大麻素组每日疼痛评分显著降低(SMD: -0.55, 95% CI: -0.69 to -0.19, 95% PI: -1.51 to 0.39, p=0.003, I2=82.49, τ2=0.20, Q-statistic=47.69, GRADE: 中等确定性)。
  • 睡眠健康和镇痛获益与日间嗜睡、恶心和头晕的更高可能性相关。
  • 大多数研究未使用经过验证的睡眠健康测量工具。

关键数值与推荐

  • 睡眠质量改善:SMD 0.40(95% CI: 0.19 to -0.61),p=0.002,GRADE中等确定性。
  • 每日疼痛评分降低:SMD -0.55(95% CI: -0.69 to -0.19),p=0.003,GRADE中等确定性。

临床怎么用

  • 大麻素可作为慢性神经病理性疼痛的治疗选择之一,需权衡睡眠和镇痛获益与日间嗜睡、恶心、头晕等不良反应风险。
  • 临床决策时应考虑大多数研究未使用验证性睡眠评估工具,证据确定性为中等。

局限性

  • 大多数研究未使用经过验证的睡眠健康测量工具。
  • 需要更多研究全面评估大麻素对睡眠健康和镇痛疗效的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic neuropathic pain is often debilitating and can have a significant impact on sleep health and quality of life. There is limited information on the impact of cannabinoids on sleep health when treating neuropathic pain. OBJECTIVE: The objectives of this systematic review and meta-analysis were to determine the effect of cannabinoids on sleep quality, pain intensity, and patient impression of treatment efficacy in patients with neuropathic pain. EVIDENCE REVIEW: Nine available medical literature databases were searched for randomized controlled trials comparing synthetic and natural cannabinoids to placebo in patients with neuropathic pain syndromes. Data on validated tools for sleep quality, pain intensity, patients' global impression of change (PGIC), and incidence of adverse effects of cannabinoids were extracted and synthesized. FINDINGS: Of the 3491 studies screened, eight randomized controlled trials satisfied the inclusion criteria for this review. Analyses were performed using R -4.1.2. using the metafor package and are interpreted using alpha=0.05 as the threshold for statistical significance. Validated measures for sleep health were not used in most studies. Meta-analysis of data from six studies showed that cannabinoids were associated with a significant improvement in sleep quality (standardized mean difference (SMD): 0.40; 95% CI: 0.19 to -0.61, 95% prediction interval (PI): -0.12 to 0.88, p-value=0.002, I2=55.26, τ2=0.05, Q-statistic=16.72, GRADE: moderate certainty). Meta-analysis of data from eight studies showed a significant reduction in daily pain scores in the cannabinoid (CB) group (SMD: -0.55, 95% CI:-0.69 to -0.19, 95% PI: -1.51 to 0.39, p=0.003, I2=82.49, τ2=0.20, Q-statistic=47.69, GRADE: moderate certainty). However, sleep health and analgesic benefits were associated with a higher likelihood of experiencing daytime somnolence, nausea, and dizziness. CONCLUSIONS: Cannabinoids have a role in treating chronic neuropathic pain as evidenced by significant improvements in sleep quality, pain intensity, and PGIC. More research is needed to comprehensively evaluate the impact of cannabinoids on sleep health and analgesic efficacy. PROSPERO REGISTRATION NUMBER: CRD42017074255.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. McParland AL, Bhatia A, Matelski J, et al. Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2022. PMID: 36598058. doi:10.1136/rapm-2021-103431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。